Results 121 to 130 of about 24,629 (256)

An Uncommon Complication of Streptokinase: Large Spontaneous Iliopsoas Hematoma

Acta Medica Iranica, 2017
Streptokinase is a fibrinolytic agent that enhances plasmin activation and is used in selected patients with acute ST elevation myocardial infarction (STEMI).
Raheleh Aliabadi, Hassan Riahi Beni, Jila Nadjafi, Morteza Hassanzade, Mehrnaz Tabrizi, Mohsen Nasiri, Gandom Sedehi, Ali Pourmojarab   +7 more
doaj  

Reversal of intraoperative arterial thrombosis with a fibrinolytic agent when treating large and giant partially thrombosed aneurysms of the middle cerebral artery [PDF]

, 2015
Shalva Eliava, Yu V Pilipenko, Oleg Shekhtman, An N Konovalov   +3 more
openalex   +1 more source

Myocardial rupture after percutaneous coronary intervention of an unstable RCA lesion in myocardial infarction and concomitant stroke treated with intravenous fibrinolytic agents: A case report

, 2021
Benjamin Bay, Christoph Waldeyer, Leander Rimmele, Stefan Blankenberg, Peter Clemmensen   +4 more
openalex   +2 more sources

Development of thermostable Streptokinase by recombinant DNA technology as fibrinolytic agent for different thromboembolic disorders [PDF]

, 2023
Mohammed Kassab
openalex   +1 more source

Two-Dimensional Transthoracic Echocardiographic Demonstration of Reduction in Fibrin Content in Purulent Pericarditis Following Intrapericardial Fibrinolytic Agent Administration

, 2021
Mahmoud Abdelsalam, Cyril Nathaniel, Zeyad M. Elmarzouky, Subash Dulal, Usama Habib, Maram Ahmed, Amir Ashiq, Navin C. Nanda   +7 more
openalex   +1 more source

Once-daily intrapleural urokinase treatment of complicated parapneumonic effusion in pediatric patients [PDF]

, 2010
In this paper, we describe our experience in the treatment of childhood empyema using urokinase. Patients' ages ranged from 2 to 12 years. Urokinase (dosage: 3,100 IU/kg/day) was diluted in normal saline to produce 1000 IU/ml (maximum dosage 100,000 IU ...
Bergamini, Barbara Maria, Bianchini, M. A., Biondini, D., Cacciari, A., Ceccarelli, P. L., Durante, V., Repetto, P.   +6 more
core  

Oral fibrinolytic agent in hyper-coagulopathy in severe COVID – 19 ARDS Patients: two case reports

Journal of the Pakistan Medical Association
The use of oral fibrinolytic agent (DLBS1033) has been proven for adjuvant treatment in venous thromboembolism, however until now there is no published report about its uses and effectiveness as an addition to the standard therapy of severe COVID-19 ...
Dimas Rio Balti, Liem Audi Natalino, Armyta Galuh, Ryan Enast Intan   +3 more
doaj   +1 more source

Intra-pleural fibrinolytic therapy versus placebo, or a different fibrinolytic agent, in the treatment of adult parapneumonic effusions and empyema. [PDF]

Cochrane Database Syst Rev, 2019
Altmann ES, Crossingham I, Wilson S, Davies HR.   +3 more
europepmc   +1 more source

In-vitro and in-silico analyses of the thrombolytic potential of green kiwifruit

Scientific Reports
Cardiovascular diseases (CVDs), mainly caused by thrombosis complications, are the leading cause of mortality worldwide, making the development of alternative treatments highly desirable.
Reinhard Pinontoan, Jonathan Suciono Purnomo, Elvina Bella Avissa, Jessica Pricilla Tanojo, Moses Djuan, Valerie Vidian, Ariela Samantha, Juandy Jo, Eden Steven   +8 more
doaj   +1 more source

Studies on Anti-atherosclerotic Agents. VII. Experimental Studies of Sodium Chondroitin Polysulfate on Hypolipemic, Anticoagulative, Fibrinolytic and Lipotropic Activities

, 1972
Toshihiro Kobayakawa
openalex   +2 more sources